The existence of a multitude of oncolytics regimens containing two or more agents (combination) outlines the need to define their most adequate sequence of administration. However, limited resources are currently available to specify a particular sequence, presenting challenges potentially impacting on patient safety, and Pharmacy & Infusion Nursing workflows.
Methods
A comprehensive literature search was performed leading to the compilation of a document containing drug administration sequencing instructions for our Nursing, Pharmacy, and Oncology providers to follow. Regimens prioritized in our literature review represented regimens selected as part of our approved Clinical Pathways, regimens inquiries from Pharmacy or Nursing, as well as less frequently used regimens. We stratified the regimens by tumor type and arranged them alphabetically by indication.
Results
A table was compiled containing all the supporting literature for the recommended drug administration sequences. If, in certain instances, no literature support was identified outlining rationale such as enhanced management of adverse effects, a specific institutional decision was made by our enterprise Medical Oncology Committee with recommendations from Pharmacy experts. The primary guiding principles for outlining our recommendations were the following: administration of vesicant agents first; administration of biologic agents first; administration of taxanes prior to platinum agents; and duration of infusion (shorter infusions prioritized).
Conclusion
This guideline is not exhaustive. The compilation provided here is intended to be utilized as guidance for oncolytics administration sequence. We will continue to review and incorporate treatment sequencing recommendations for additional regimens.
WierzbowskaARobakTPlutaA, et al.
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G‐CSF (CLAG‐M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.Eur J Haematol2008;
80: 115–126.
De SantisMBellmuntJMeadG, et al.
Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer “unfit” for cisplatin-based chemotherapy: phase II – results of EORTC study 30986.J Clin Oncol2008;
27: 5634–5639.
11.
KaufmanDSWinterKAShipleyWU, et al.
Phase I–II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, PACLitaxel, CISplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology2009;
73: 833–837.
12.
DragnevKHHardinSBPipasJM, et al.
A dose escalation trial of biweekly DOCEtaxel and gemcitabine with filgrastim or pegfilgrastim for the treatment of patients with advanced solid tumors.Chemotherapy2010;
56: 135–141.
13.
DreicerRManolaJSchneiderDJ, et al.; Eastern Cooperative Oncology Group.
Phase II trial of gemcitabine and DOCEtaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group.Cancer2003;
97: 2743–2747.
SternbergCNde MulderPSchornagelJH, et al.
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.Eur J Cancer2006;
42: 50–54.
16.
PlimackERHoffman-CensitsJHViterboR, et al.
Accelerated methotrexate, vinBLAStine, DOXOrubicin, and CISplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity.J Clin Oncol2014;
32: 1895–1901.
17.
International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group),
the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group, the Australian Bladder Cancer Study Group, the National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologico Group. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894trial. J Clin Oncol2011;
29: 2171–2177.
DreicerRManolaJRothBJ, et al.
Phase III trial of methotrexate, vinBLAStine, DOXOrubicin, and CISplatin versus CARBOplatin and PACLitaxel in patients with advanced carcinoma of the urothelium.Cancer2004;
100: 1639–1645.
BernsteinMLDevidasMLafreniereD, et al.
Intensive therapy with growth factor support for patients with ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children’s Cancer Group Phase II Study 9457 – a report from the Children’s Oncology Group. J Clin Oncol2006;
24: 152–159.
JonesSEColleaRPaulD, et al.
Adjuvant docetaxel and cyclophosphamide plus trastuzumab in patients with HER2-amplified early stage breast cancer: a single-group, open-label, phase 2 study.Lancet Oncol2013;
14: 1121–1128.
27.
MartinMPienkowskiTMackeyJ, et al.
Adjuvant docetaxel for node-positive breast cancer.N Engl J Med2005;
352: 2302–2313.
28.
ManciniRModlinJ.Chemotherapy administration sequence: a review of the literature and creation of a sequencing chart. J Hematol Oncol Pharm2011;
1: 17–25.
Von MinckwitzGProcterMde AzambujaE, et al.
Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.N Engl J Med2017;
377: 122–131.
31.
SlamonDEiermannWRobertN, et al.; Breast Cancer International Research Group.
Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med2011;
365: 1273–1283.
32.
NabholtzJMFalksonCCamposD, et al.
DOCEtaxel and DOXOrubicin compared with DOXOrubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.J Clin Oncol2003;
21: 968–975.
33.
LangleyRECarmichaelJJonesAL, et al.
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute Trial AB01.J Clin Oncol2005;
23: 8322–8330.
34.
O’ShaughnessyJOsborneCPippenJE, et al.
Iniparib plus chemotherapy in metastatic triple negative breast cancer.N Engl J Med2011;
364: 205–214.
35.
AlbainKSNagSMCalderillo-RuizG, et al.
Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.J Clin Oncol2008;
26: 3950–3957.
36.
AnderssonMLidbrinkEBjerreK, et al.
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2 – positive breast cancer: the HERNATA study.J Clin Oncol2011;
29: 264–271.
37.
VredenburghJJDesjardinsAHerndonJEII, et al.
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.Clin Cancer Res2007;
13: 1253–1259.
38.
VredenburghJJDesjardinsAHerndonJEII, et al.
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.J Clin Oncol2007;
25: 4722–4729.
39.
MassiminoMSpreaficoFRivaD, et al.
A lower-dose, lower-toxicity cisplatin–etoposide regimen for childhood progressive low-grade glioma.J Neurooncol2010;
100: 65–71.
40.
VelasquezWSCabanillasFSalvadorP, et al.
Effective salvage therapy for lymphoma with cisplatin in combination with high-dose ara-C and dexamethasone (DHAP).Blood1988;
71: 117–122.
41.
PackerRJGajjarAVezinaG, et al.
Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma.J Clin Oncol2006;
24: 4202–4208.
42.
ShahGDYahalomJCorreaDD, et al.
Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.J Clin Oncol2007;
25: 4730–4735.
PetersWAIIILiuPYBarrettRJII, et al.
Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.J Clin Oncol2000;
18: 1606–1613.
KabbinavarFHurwitzHIFehrenbacherL, et al.
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.J Clin Oncol2003;
21: 60–65.
AllegraCJYothersGO’ConnellMJ, et al.
Bevacizumab in stage II-III colon cancer: 5-year update of the national surgical adjuvant breast and bowel project C-08 trial.J Clin Oncol2013;
31: 359–364.
FalconeARicciSBrunettiI, et al.
Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.J Clin Oncol2007;
25: 1670–1676.
58.
CassidyJClarkeSDı´az-RubioE, et al.
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.J Clin Oncol2008;
26: 2006–2012.
59.
CremoliniCLoupakisFAntoniottiC, et al.
FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol2015;
16: 1306–1315.
60.
Martín-MartorellPRosellóSRodríguez-BraunE, et al.
Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial.Br J Cancer2008;
99: 455–458.
61.
PeetersMPriceTJCervantesA, et al.
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.J Clin Oncol2010;
28: 4706–4713.
DouillardJ-YSienaSCassidyJ, et al.
Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study.J Clin Oncol2010;
28: 4697–4705.
65.
CassidyJClarkeSDíaz-RubioE, et al.
Randomized phase III study of capecitabine PluscOxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.J Clin Oncol2008;
26: 2006–2012.
66.
FolprechtGGruenbergerTBechsteinWO, et al.
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol2010;
11: 38–47.
67.
HallerDGRothenbergMLWongAO, et al.
Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma.J Clin Oncol2008;
26: 4544–4550.
68.
AndréTBlonsHMabroM, et al.
for the GERCOR; Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study.Ann Oncol2013;
24: 412–419.
69.
AndréTQuinauxELouvetC, et al.
Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1.J Clin Oncol2007;
25: 3732–3738.
LorenzenSSchusterTPorschenR, et al.
Cetuximab plus cisplatin–5-fluorouracil versus cisplatin–5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.Ann Oncol2009;
20: 1667–1673.
ShahMAJanjigianYYStollerR, et al.
Randomized multicenter phase II study of modified docetaxel, cisplatin, and fluorouracil (DCF) versus DCF plus growth factor support in patients with metastatic gastric adenocarcinoma: a study of the US Gastric Cancer Consortium.J Clin Oncol2015;
33: 3874–3879.
75.
BurtnessBGibsonMEglestonB, et al.
Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.Ann Oncol2009;
20: 1242–1248.
76.
CunninghamDStarlingNRaoS, et al.
for the Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer.N Engl J Med2008;
358: 36–46.
77.
SumpterKHarper-WynneCCunninghamD, et al.
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.Br J Cancer2005;
92: 1976–1983.
78.
HomannNPauligkCLuleyK, et al.
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5-fluorouracil, OXALIplatin and DOCEtaxel.Int J Cancer2012;
130: 1706–1713.
79.
IlsonDH.Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology2004;
18(14 Suppl 14): 22–25.
WilkeHMuroKVan CutsemE, et al.; RAINBOW Study Group.
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.Lancet Oncol2014;
15: 1224–1235.
BurtnessBGoldwasserMAFloodW, et al.
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group Study.J Clin Oncol2005;
23: 8646–8654.
87.
VermorkenJBMesiaRRiveraF, et al.
Platinum-based chemotherapy plus cetuximab in head and neck cancer.N Engl J Med2008;
359: 1116–1127.
DovalDCSekhonJSGuptaSK, et al.
A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.Br J Cancer2004;
90: 1516–1520.
KaufmanDSWinterKAShipleyWU, et al.
Phase I-II RTOG Study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, PACLitaxel, CISplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology2009;
73: 833–837.
Van HaarstJMBaasPManegoldCh, et al.
Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma.Br J Cancer2002;
86: 342–345.
FlahertyLEOthusMAtkinsMB, et al.
Southwest Oncology Group S0008: a phase III trial of high-dose interferon α-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma – an intergroup study of cancer and leukemia Group B, Children’s Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group.J Clin Oncol2014;
32: 3771–3778.
103.
LarkinJChiarion-SileniVGonzalezR, et al.
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma.N Engl J Med2015;
373: 23–34.
HauschildAAgarwalaSSTrefzerU, et al.
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.J Clin Oncol2009;
27: 2823–2830.
106.
FlinnIWvan der JagtRKahlBS, et al.
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study.Blood2014;
123: 2944–2952.
107.
DunleavyKPittalugaSMaedaLS, et al.
Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.N Engl J Med2013;
368: 1408–1416.
108.
WilsonWHGrossbardMLPittalugaS, et al.
Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy.Blood2002;
99: 2685–2693.
109.
CrumpMKuruvillaJCoubanS, et al.
Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12.J Clin Oncol2014;
32: 3490–3496.
110.
CrumpMBaetzTCoubanS, et al.
Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma. A phase II study by the National Cancer Institute of Canada Clinical Trials Group (NCIC‐CTG).Cancer2004;
101: 1835–1842.
111.
OguraMTobinaiKHatakeK, et al.
Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.Clin Cancer Res2016;
22: 4807–4816.
112.
SanghaRDaviesADangNH, et al.
Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.J Drug Assess2017;
6: 10–17.
113.
KewalramaniTZelenetzADNimerSD, et al.
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood2004;
103: 3684–3688.
FossellaFPereiraJRvon PawelJ, et al.
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non–small-cell lung cancer: the TAX 326 study group.J Clin Oncol2003;
21: 3016–3024.
116.
SocinskiMABondarenkoIKarasevaNA, et al.
Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non–small-cell lung cancer: final results of a phase III trial.J Clin Oncol2012;
30: 2055–2062.
117.
SenanSBradeAWangL-h, et al.
PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non–small-cell lung cancer.J Clin Oncol2016;
34: 953–962.
118.
PatelJDSocinskiMAGaronEB, et al.
PointBreak: a randomized phase III study of pemetrexed plus CARBOplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus PACLitaxel plus CARBOplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non–small-cell lung cancer.J Clin Oncol2013;
31: 4349–4357.
119.
GovindanRBogartJStinchcombeT, et al.
Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: cancer and leukemia group B trial 30407.J Clin Oncol2011;
29: 3120–3125.
SchillerJHHarringtonDBelaniCP, et al.
for the Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med2002;
346: 92–98.
124.
U.S. National Library of Medicine. Chemotherapy and radiation in treating participants with stage 3 non-small cell lung cancer (PROCLAIM) NCT00686959, 2018.
125.
ShapiroGITibesRGordonMS, et al.
Phase I studies of CBP501, a G2 checkpoint abrogator, as monotherapy and in combination with cisplatin in patients with advanced solid tumors.Clin Cancer Res2011;
17: 3431–3442.
126.
MastersGAArgirisAEHahnEA, et al.
A randomized phase II trial using two different treatment schedules of gemcitabine and carboplatin in patients with advanced non–small-cell lung cancer.J Thorac Oncol2006;
1: 19–24.
127.
PujolJ-LBretonJ-LGervaisR, et al.
Gemcitabine–DOCEtaxel versus CISplatin–vinORELBine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for CISplatin.Ann Oncol2005;
16: 602–610.
CheesemanSLJoelSPChesterJD, et al.
A ‘modified de Gramont’ regimen of fluorouracil, alone and with oxaliplatin, for advanced colorectal cancer.Br J Cancer2002;
87: 393–399.
BriasoulisEKalofonosHBafaloukosD, et al.
Carboplatin plus paclitaxel in unknown primary carcinoma: a Phase II Hellenic Cooperative Oncology Group Study.J Clin Oncol2000;
18: 3101–3107.
PentheroudakisGBriasoulisEKalofonosHP, et al.
Docetaxel and carboplatin combination chemotherapy as outpatient palliative therapy in carcinoma of unknown primary: a multicentre Hellenic Cooperative Oncology Group phase II study.Acta Oncol2008;
47: 1148–1155.
PointreauYGaraudPChapetS, et al.
Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation.J Natl Cancer Inst2009;
101: 498–506.
139.
PouesselDCulineSBechtC, et al.
Gemcitabine and docetaxel as front-line chemotherapy in patients with carcinoma of an unknown primary site. Cancer2004;
100: 1257–1261.
ParkYHRyooB-YChoiS-J, et al.
A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.Japan J Clin Oncol2004;
34: 681–685.
142.
ColemanRLBradyMFHerzogTJ, et al.
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol2017;
18: 779–791.
VaseyPA.On behalf of the Scottish Gynaecological Cancer Trials Group,
Gordon C. Jayson, On behalf of the Scottish Gynaecological Cancer Trials Group, Alan Gordon, On behalf of the Scottish Gynaecological Cancer Trials Group, Hani Gabra, On behalf of the Scottish Gynaecological Cancer Trials Group, Rob Coleman, On behalf of the Scottish Gynaecological Cancer Trials Group, Ronnie Atkinson, On behalf of the Scottish Gynaecological Cancer Trials Group, David Parkin, On behalf of the Scottish Gynaecological Cancer Trials Group, James Paul, On behalf of the Scottish Gynaecological Cancer Trials Group, Andrea Hay, On behalf of the Scottish Gynaecological Cancer Trials Group, Stan B. Kaye, On behalf of the Scottish Gynaecological Cancer Trials Group; Phase III randomized trial of docetaxel–carboplatin versus paclitaxel–carboplatin as first-line chemotherapy for ovarian carcinoma.J Natl Cancer Inst2004;
96: 1682–1691.
145.
VerschraegenCFCzokSMullerCY, et al.
Phase II study of bevacizumab with liposomal doxorubicin for patients with platinum- and taxane-resistant ovarian cancer.Ann Oncol2012;
23: 3104–3110.
FerreroJ-MWeberBGeayJ-F, et al.
Second-line chemotherapy with pegylated liposomal doxorubicin and carboplatin is highly effective in patients with advanced ovarian cancer in late relapse: a GINECO phase II trial.Ann Oncol2007;
18: 263–268.
PfistererJPlanteMVergoteI, et al.
Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.J Clin Oncol2006;
24: 4699–4707.
150.
AghajanianCBlankSVGoffBA, et al.
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.J Clin Oncol2012;
30: 2039–2045.
KondaguntaGVBacikJDonadioA, et al.
Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors.J Clin Oncol2005;
23: 6549–6555.
153.
OettleHRiessHStielerJM, et al.
Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.J Clin Oncol2014;
32: 2423–2429.
154.
GhosnMFarhatFKattanJ, et al.
FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.Am J Clin Oncol2007;
30: 15–20.
155.
Wang-GillamALiC-PBodokyG, et al.
Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet2016;
387: 545–557.
156.
ConroyTDesseigneFYchouM, et al.
for the Groupe Tumeurs Digestives of Unicancer and the PRODIGE Intergroup. Folfirinox versus gemcitabine for metastatic pancreatic cancer.N Engl J Med2011;
364: 1817–1825.
157.
FineRLFogelmanDRSchreibmanSM, et al.
The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.Cancer Chemother Pharmacol2008;
61: 167–175.
Von HoffDDErvinTArenaFP, et al.
Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.N Engl J Med2013;
369: 1691–1703.
160.
TaylorSG IVMurthyAKVannetzelJM, et al.
Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer.J Clin Oncol1994;
12: 385–395.
161.
AjaniJAWinterKAGundersonLL, et al.
Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.JAMA2008;
299: 1914–1921.
162.
PagliaroLCCrookJ.Multimodality therapy in penile cancer: when and which treatments?World J Urol2009;
27: 221–225.
163.
PagliaroLCWilliamsDLDalianiD, et al.
Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.J Clin Oncol2010;
28: 3851–3857.
164.
SchmittelAvon WeikersthalLFSebastianM, et al.
A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.Ann Oncol2006;
17: 663–667.
165.
ChenGHuynhMFehrenbacherL, et al.
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer.J Clin Oncol2009;
27: 1401–1404.
166.
EvansWKShepherdFAFeldR, et al.
VP-16 and cisplatin as first-line therapy for small-cell lung cancer.J Clin Oncol1985;
3: 1471–1477.
167.
ZalupskiMMetchBBalcerzakS, et al.
Phase III comparison of DOXOrubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.J Natl Cancer Inst1991;
83: 926–932.
168.
AntmanKCrowleyJBalcerzakSP, et al.
An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas.J Clin Oncol1993;
11: 1276–1285.
169.
JudsonIVerweijJGelderblomH, et al.
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.Lancet Oncol2014;
15: 415–423.
170.
BayJ-ORay-CoquardIFayetteJ, et al. and for the Groupe Sarcome Français.
DOCEtaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis.Int J Cancer2007;
119: 706–711.
DileoPMorganJAZahriehD, et al.
Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial.Cancer2007;
109: 1863–1869.
PectasidesDPectasidesMFarmakisD, et al.
Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.Ann Oncol2004;
15: 493–497.
175.
FlemingGFBrunettoVLCellaD, et al.
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.J Clin Oncol2004;
22: 2159–2166.
176.
SosaJAEliseiRJarzabB, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. Epub ahead of print 11 February 2014. DOI: 10.1089/thy.2013.0078.
177.
FlemingGFBrunettoVLCellaD, et al.
Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.J Clin Oncol2004;
22: 2159–2166.
HensleyMLIshillNSoslowR, et al.
Adjuvant gemcitabine plus docetaxel for completely resected stages I–IV high grade uterine leiomyosarcoma: results of a prospective study.Gynecol Oncol2009;
179: 563–567.
180.
HensleyMLBlessingJAMannelR, et al.
Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial.Gynecol Oncol2008;
109: 329–334.
181.
WolfsonAHBradyMFRoceretoT, et al.
A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus.Gynecol Oncol2007;
107: 177–185.
182.
U.S. National Library of Medicine. Paclitaxel and carboplatin or ifosfamide in treating patients with newly diagnosed, persistent or recurrent uterine, ovarian, fallopian tube, or peritoneal cavity cancer NCT00954174, 2018.
183.
U.S. National Library of Medicine. Evaluation of paclitaxel (Taxol, NSC #673089), carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the treatment of advanced, persistent, or recurrent uterine carcinosarcoma NCT00687687.
184.
AghajanianC1SillMWSecordAA, et al.
Iniparib plus paclitaxel and carboplatin as initial treatment of advanced or recurrent uterine carcinosarcoma: a Gynecologic Oncology Group Study.Gynecol Oncol2012;
126: 424–427.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
